Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Pericarditis III: Medical Management

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

Inflammatory Bowel Disease V: Surgical Management

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular constraints of sarcopenia in the ageing muscle.

Frontiers in aging·2025

Same author

Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.

European review for medical and pharmacological sciences·2022

Same author

Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.

Journal of neuroimmunology·2021

Same author

Efficacy of mechanical thrombectomy in patients with ischemic stroke and cancer.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2021

Same author

Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients.

Molecular neurobiology·2021

Same author

Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.

Journal of neuroimmunology·2021

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Refractory Takayasu arteritis successfully treated with infliximab.

S Maffei¹, M Di Renzo, S Santoro

¹Department of Cardiology, Policlinico Le Scotte, University of Siena, Italy.

European Review for Medical and Pharmacological Sciences

|April 15, 2009

Summary

Infliximab, an anti-tumor necrosis factor-alpha (TNF-alpha) drug, effectively treated a patient with Takayasu arteritis (TA) unresponsive to standard therapies. This offers a new treatment avenue for refractory TA patients.

Related Experiment Videos

Last Updated: Jun 24, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Area of Science:

Immunology
Rheumatology
Vascular Medicine

Background:

Takayasu arteritis (TA) is a large vessel vasculitis characterized by chronic inflammation, leading to stenosis or aneurysms.
Elevated proinflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), are implicated in TA pathogenesis.
Conventional treatments often fail to achieve clinical remission in TA patients.

Observation:

A patient with Takayasu arteritis demonstrated resistance to conventional therapeutic approaches.
Infliximab, a monoclonal antibody targeting TNF-alpha, was administered to the refractory patient.
The patient experienced a clinical remission of Takayasu arteritis following infliximab treatment.

Findings:

Infliximab effectively neutralized TNF-alpha, a key inflammatory mediator in TA.
Successful clinical remission was achieved in a patient with treatment-resistant Takayasu arteritis.
This case highlights the therapeutic potential of anti-TNF-alpha agents in refractory TA.

Implications:

Infliximab represents a promising therapeutic option for Takayasu arteritis patients refractory to conventional therapy.
Targeting TNF-alpha may be a viable strategy for managing severe or treatment-resistant TA.
Further research is warranted to confirm the efficacy and safety of infliximab in a broader TA population.